You are viewing the site in preview mode
Skip to main content
Source
Acute Attacks*
Hydrocele
Lymphoedema
Drug
Drug delivery strategy
Follow-up interval
Ciferri 1969 [170]
+
--
--
DEC
MDA
2 years
March 1960 [171]
+
+
+
DEC
MDA
10 years
Bernhard 2001 [169]
.
--
.
DEC
MDA, clinical trial
1 year
Partono 1989 [172]
+
.
+
DEC
MDA, selective
11 years
Beye 1952 [173]
--
--
--
DEC
MDA, selective
16 months
Simonsen 1995 [174]
.
--**
.
DEC
Selective
1 year
Kessel 1957 [175]
+
.
.
DEC
Selective
1 year
Fan 1995 [176]
.
--
--
DEC
Salt
16–19 years
Meyrowitch 1996 [177]
.
+
+
DEC
Salt
2 years
Meyrowitch 1998 [178]
.
+
.
DEC
Salt
4 years
Meyrowitch 2004 [179]
.
+¶
.
DEC
MDA, salt
4 years
Hewitt 1950 [180]
+
+¶
+¶
DEC
Clinical trial
8–14 months
Das 2003 [167]
.
.
--
DEC
Clinical trial
1 year
Kenney 1949 [181]
.
.
+
DEC
Clinical trial
1–3 months
Pani 1989 [51]
.
.
+‡
DEC
Clinical trial†
>1 year
Moore 1996 [16]
.
.
+
DEC
Case report
1 week-7 months
Bockarie 2002 [18]
.
+
+
DEC, DEC+IV
MDA
5 years
Dunyo 2000 [182]
.
--
--
IV + Alb
MDA
1 year
* Acute dermatolymphangioadenitis and filarial lymphangitis were not distinguished in most studies
** 2 of 8 hydroceles resolved
¶Disease progression also observed
‡ Reductions seen primarily in patients with early-stage disease
† Included other interventions, but improvement related to number of DEC doses
+ Decrease in size, incidence, or prevalence noted (not necessarily statistically significant)
-- No decrease noted (or if noted, inconsistent or not considered significant by authors)
. Not evaluated or extremely small numbers
DEC Diethylcarbamazine
IV Ivermectin
Alb Albendazole
MDA Mass drug administration using tablets
Salt DEC-fortified salt
Selective Treatment only of persons known to be infected or with clinical disease
